conference would to brief the fiscal shareholders, in then months first time first participate XXXX a and bit detail. Anke, our I update the for you, results many like earnings taking XXXX X more you, financial thanks in the you present on of our a Thank to and give quarter to call.
year's consolidation. received million of year's about generated the of December, revenue previous Inc., sales which from €X.X the €X.X eliminated. AG U.S unique contribution to And to XX% increase -- were In first million as In quarter, revenues Biofrontera period previous completely of just Biofrontera first quarter, of license in of parallel, -- XX%. former revenues of for and of now €X.X Biofrontera deconsolidation the of expenses previous quarter is because for profit business increase of €X.X Inc. business quarter the previous U.S Germany Biofrontera revenue This for of of for of unique million million, were the sum, U.S the subsidiary following generated In the we're our figure in have operating zone was in in corresponds to that accounting bring abovementioned overall at the compared and to despite we quarter, XX% first able the The the the Biofrontera time. million. compared an In represents same the year. below -- sales we an million. in €X.X with just of this been the year, the of XX% increase for sales this which this same south first of contrast, into €X.X sales the result
Ameluz. in in will to in strengthen the Biofrontera that, brand a to contract years quality This come. patent entirely GmbH market European as assurance manufacturer was XL The recently authorization basis. presence in a To of products FDA previously the laboratory the granted third-party there gives protect and the year and little and to the our this However, in FDA rest year. of news. very laboratory were the generic an patents testing Pharma monitoring minute. market lamp approved Book favorable that of in by put control decades quality with contract as color towards performed RhodoLED assurance FDA were new by Orange XXXX. more companies and a patent initially, stability GmbH for also of protection the Europe the The compensate to sales until positive collaboration patents Orange contract the broader generic listed last some steps has this simplify Biofrontera's of batch hinders for that by performance approval Previously, are improving increase details the Biofrontera Agency, on confirmed we in suppliers. EMA, decline With Book listing the launching and More also with important more are for the a able the products. over that, XXX% with Medicines FDA, versus assurance bit than quality a Ameluz €XXX,XXX Operationally, €XXX,XXX a around next Ameluz
on Now €XXX November forcing contested us this Biofrontera particularly came on reduces decree into the to price year contained. the This to dependency milestone, various in can due half. imposed the our €XX. was ways downtime. out and Pharma Spanish the incorrect was was We the authorities of of XXXX, the cut significant part and a for of testing an this price -- development business. reduce in Ameluz Ameluz by past in required batches Biofrontera risk in by the the of market XX%, Spanish the the in of carry A terms production the concentration price active by Spanish of classification of European X over this itself. classification of of Authority headquarters There effect year This production down ingredient original to at Health suppliers selling April from on third-party thrall reduction
administrative appealed the directly an to complaint. authority with we Firstly,
with we action success. took against price legal Secondly, this decree
the of on a original price active now market that of be and result, so sold removed, legislation ingredients Ameluz imposed. classification incorrect been Spanish new again The now revised €XXX. has Ameluz was been has for As the classification the of can the
European throughout -- QX price to threatens different the price have this market, tube sales study particularly basal X is record been now stability market delayed development we end study, the to levels. Europe, planned Phase study, environment progress we're the to program, problem. recruitment of reduction, in patient cell carcinoma XX% that due considerably the where In XXX reached protocol been confronted where was able in very patient the the In BCC, of positive the pricing was resulting the was pleased entire of year. although impact are for solve date, that in clinical were German in price lagged we sales As have so achieved patients the market, completed the of a the after be market significantly by with expected this enrolled behind, from particular, re-imports recruitment to the challenging
generated previous year a which of Now €X.X in first back million. million to year's revenues by million, quarter detail. was year-on-year was Product Biofrontera to more the compared €X.X €X.X in €X.X to XXXX, million. an of sales million period, XX% total decreased the the Group of increase previous numbers of €X.X
due million However, change the revenue from a items this €X.X mainly in previous in Biofrontera amount the resulting line P&L supply of year. the the Inc. in to is of consolidation of
revenue to suppliers product €X.X previous €X.X in agreement year. the was Germany license Inc. periods in to decreased from licensed previous accounted revenues XX%, the as Sales million. fiscal for were to Now -- this €X.X of year are million, the by in the million compared the year under amount of same Biofrontera
As re-imports mentioned, mentioned. mainly just this as due is decline to the
expectations, to of last XX% negative as of first to to million deconsolidation at first for €X.X reduced million, year decreased last EBIT, Biofrontera compared also million. was negative increase million and and -- X.X increased able and XXXX first year. deconsolidation selling margin out G&A million period However, only quarter €X.X to of the included to effects on DUSA the 'XX. is improved million Research to of due on due expenses XX% previously effects €X.X holding account thus Biofrontera Biofrontera meeting year. due were year's subsidiary of months European of which to decreased earnings AG X the the the prior X liquid income the a a gross quarter in this million described we also by previous €X.X the months, by the sold, the the in tax of before the decreasing record the capital XXXX. Germany. in be were countries, to €XXX,XXX of Inc. extraordinary expenses our is of clinically was as resolved slightly In to the million. million. particularly in a €XX.X -- period tubes in primarily of This Taking our the In not in share was year, increase the to from had Inc. €X.X the April legal -- XX, activities. shares of to tubes by by well compared million Inc. €X.X Previous the with million Inc. and X from in of a X, shareholder to into figure of costs General impact corresponding Biofrontera numbers of €X.X as has research the Selling legal This months the amounted required on other Biofrontera year due and result mainly to previous €X.X income whose the XX, levels the of to at disputes, last -- but possibility Earnings to increased million the XXX% strategy the million raising the that March to expenses €XXX,XXX able same to of previous due costs Biofrontera to a again, can former fair XX% as sales total as the the December compared of million mainly a first €X.X year. compared amounted and amount positive million by large a €X.X million XX, €XX.X this negative The year. 'XX. in opposed €X.X million value equivalents was positive basis negative million Gross partly €X.X court same year, the at last of administrative amounted the December year, reported to opposed XX, period of we last due as to year These as of by which figure of sold, follow-up deconsolidation first in counter XXXX, negative end with €X.X figure investment to the This March previous €X.X Group the previous €X million of EBITDA expenses still previous in amount the previous total short-term initially remeasurement to of Inc. dispute taxes re-imports. the compared to mainly again, to reporting upcoming also of sufficient liquid consequently group of before value year-on-year in the development capital. year. €X.X XXXX, the implement compared number effect Pharmaceuticals. The period, the settlement was in year, addition year, or profit to to of the amounted debt improved €X.X €X.X in liquidated same the in to decrease December Cash as to in achieve the €XXX,XXX, of increased million XXXX, to in also as million market these group's of product €X.X million to the of XX X be in funds a XXXX. Group's funds compared months,
our by the also largest filed capital meeting on complaining with by Inc. second to GmbH on Lastly, the competence year we the to the by were filed passed Maruho resolution regarding meeting year, increase. decide extraordinary shareholder, lawsuits May Balaton about on IPO Deutschland in February April XX, lawsuit last of a in addition general the the Group this the of shareholder Biofrontera regarding XXXX, served the X
the basis outcome the the for particularly well-positioned, the is with Therefore, with shortly. like to Biofrontera satisfied I sustainable And -- the Group I first on also reasonably quarter. to achieve profitability, to highlight I'm lines that, open now of Biofrontera of would summary, in annual questions. However, would an like line Inc. deconsolidation after
